{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(8)"],"submitter":["Tong Q"],"pubmed_abstract":["Glucocorticoid-induced TNF receptor-related (GITR) can act as a co-stimulatory receptor, representing a potential target for safely enhancing immunotherapy efficacy. GITR is triggered by a GITR ligand or an agonist antibody and activates CD8<sup>+</sup> and CD4<sup>+</sup> effector T cells, reducing tumor-infiltrating Treg numbers and resulting in activation of immune responses and tumor cell destruction by effector T cells. GITR is an attractive target for immunotherapy, especially in combination therapy with immune checkpoint inhibitors, as is being explored in clinical trials. Using H2L2 transgenic mice encoding the human immunoglobulin variable region and hybridoma technology, we generated a panel of fully human antibodies that showed excellent specific affinity and strong activation o"],"journal":["FEBS open bio"],"pagination":["1542-1557"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9340783"],"repository":["biostudies-literature"],"pubmed_title":["Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice."],"pmcid":["PMC9340783"],"pubmed_authors":["Liu H","Tong Q","Dai C","Qian F","Yang T","Qi Q"],"additional_accession":[]},"is_claimable":false,"name":"Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice.","description":"Glucocorticoid-induced TNF receptor-related (GITR) can act as a co-stimulatory receptor, representing a potential target for safely enhancing immunotherapy efficacy. GITR is triggered by a GITR ligand or an agonist antibody and activates CD8<sup>+</sup> and CD4<sup>+</sup> effector T cells, reducing tumor-infiltrating Treg numbers and resulting in activation of immune responses and tumor cell destruction by effector T cells. GITR is an attractive target for immunotherapy, especially in combination therapy with immune checkpoint inhibitors, as is being explored in clinical trials. Using H2L2 transgenic mice encoding the human immunoglobulin variable region and hybridoma technology, we generated a panel of fully human antibodies that showed excellent specific affinity and strong activation o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-31T15:49:00.394Z","creation":"2024-12-04T01:09:10.115Z"},"accession":"S-EPMC9340783","cross_references":{"pubmed":["35674216"],"doi":["10.1002/2211-5463.13451"]}}